Transgene SA TRGNF Stock
Transgene SA Price Chart
Transgene SA TRGNF Financial and Trading Overview
| Transgene SA stock price | 1.62 USD |
| Previous Close | 2 USD |
| Open | 2.04 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 2 - 2 USD |
| 52 Week Range | 0.01 - 2.8 USD |
| Volume | 50 USD |
| Avg. Volume | 9 USD |
| Market Cap | 212.45M USD |
| Beta (5Y Monthly) | 0.767816 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TRGNF Valuation Measures
| Enterprise Value | 186.53M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.4390244 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.765322 |
| Price/Book (mrq) | 5.277045 |
| Enterprise Value/Revenue | 18.232 |
| Enterprise Value/EBITDA | -6.586 |
Trading Information
Transgene SA Stock Price History
| Beta (5Y Monthly) | 0.767816 |
| 52-Week Change | -28.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.8 USD |
| 52 Week Low | 0.01 USD |
| 50-Day Moving Average | 2.04 USD |
| 200-Day Moving Average | 0.66 USD |
TRGNF Share Statistics
| Avg. Volume (3 month) | 9 USD |
| Avg. Daily Volume (10-Days) | 40 USD |
| Shares Outstanding | 100.2M |
| Float | 33.92M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 1.82% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -293.33% |
| Gross Margin | -214.41% |
| EBITDA Margin | -276.82% |
Management Effectiveness
| Return on Assets (ttm) | -22.29% |
| Return on Equity (ttm) | -62.45% |
Income Statement
| Revenue (ttm) | 10.23M USD |
| Revenue Per Share (ttm) | 0.1 USD |
| Quarterly Revenue Growth (yoy) | -66.20% |
| Gross Profit (ttm) | -21937000 USD |
| EBITDA | -28322000 USD |
| Net Income Avi to Common (ttm) | -32804000 USD |
| Diluted EPS (ttm) | -0.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 26.83M USD |
| Total Cash Per Share (mrq) | 0.27 USD |
| Total Debt (mrq) | 13.52M USD |
| Total Debt/Equity (mrq) | 35.73 USD |
| Current Ratio (mrq) | 3.638 |
| Book Value Per Share (mrq) | 0.379 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20303000 USD |
| Levered Free Cash Flow (ttm) | -22872376 USD |
Profile of Transgene SA
| Country | United States |
| State | N/A |
| City | Illkirch-Graffenstaden |
| Address | 400, boulevard Gonthier d’Andernach |
| ZIP | 67405 |
| Phone | 33 3 88 27 91 00 |
| Website | https://www.transgene.fr |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 146 |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Q&A For Transgene SA Stock
What is a current TRGNF stock price?
Transgene SA TRGNF stock price today per share is 1.62 USD.
How to purchase Transgene SA stock?
You can buy TRGNF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Transgene SA?
The stock symbol or ticker of Transgene SA is TRGNF.
Which industry does the Transgene SA company belong to?
The Transgene SA industry is Biotechnology.
How many shares does Transgene SA have in circulation?
The max supply of Transgene SA shares is 100.85M.
What is Transgene SA Price to Earnings Ratio (PE Ratio)?
Transgene SA PE Ratio is now.
What was Transgene SA earnings per share over the trailing 12 months (TTM)?
Transgene SA EPS is -0.38 USD over the trailing 12 months.
Which sector does the Transgene SA company belong to?
The Transgene SA sector is Healthcare.